QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
LON:VEC

Vectura Group (VEC) Share Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)
Free VEC Stock Alerts
Compare
Today's Range
N/A
50-Day Range
164.80
▼
164.80
52-Week Range
N/A
Volume
203,761 shs
Average Volume
3.37 million shs
Market Capitalization
£1.01 billion
P/E Ratio
8.20
Dividend Yield
23.06%
Price Target
N/A
Stock Analysis
Stock Analysis
VEC stock logo

About Vectura Group Stock (LON:VEC)

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

VEC Stock News Headlines

April 16, 2024 | finance.yahoo.com
Walmart chooses Swisslog ASRS powered by SynQ software to enhance transparency and delivery of quality products in third milk processing facility
February 3, 2024 | finance.yahoo.com
Global Smart Inhalers Market to Surpass 51.85 Billion by 2030 Driven by Increasing Prevalence of Chronic Respiratory Diseases
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
January 16, 2024 | finance.yahoo.com
Philip Morris (PM) Poised Well on Pricing, Smoke-Free Strength
October 6, 2023 | lse.co.uk
VEC.L Regulatory News
September 20, 2023 | msn.com
Philip Morris (NYSE:PM) Mulls Stake Sale in Pharma Unit
September 20, 2023 | msn.com
Tobacco Giant Philip Morris Rethinks Pharma Dive, Mulls Vectura Stake Sale Amid Challenges: Report
September 20, 2023 | msn.com
Philip Morris evaluates selling stake in pharmaceuticals unit - report
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
September 4, 2023 | washingtonpost.com
Nestle’s Lessons From Joining the Dud Deals Club
July 24, 2023 | uk.investing.com
Monday newspaper round-up: Business energy, Vectura, Rhodes fire, Barbenheimer, interest rates
July 23, 2023 | thetimes.co.uk
Blow to PMI as top executives quit Vectura
July 22, 2023 | msn.com
CITY WHISPERS: Whiff of change in the air for cannabis firms
June 10, 2023 | forbes.com
Metro Group
June 1, 2023 | ft.com
PMI should forget wellness and focus on smokers who want to quit
May 17, 2023 | marketwatch.com
Ipratropium Bromide Market Forthcoming Trends and Share Analysis by 2031
May 8, 2023 | marketwatch.com
Latest "Ipratropium Bromide Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraints
May 3, 2023 | marketwatch.com
2023-2030 Targeted Drug Delivery System Market Size (Growth and Outlook) includes Latest Development | with [124 Pages]
April 30, 2023 | marketwatch.com
Nebulizers Market is poised to cross USD 1.9 billion by 2032
April 25, 2023 | marketwatch.com
Ipratropium Bromide Market Manufacturing Cost Structure By 2030
April 22, 2023 | marketwatch.com
2023-2030 Potassium Gluconate Market Size with [96 Pages] includes Market Restraints | New Report by Absolute Reports
April 3, 2023 | finance.yahoo.com
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
March 28, 2023 | marketwatch.com
Polymers Drug Delivery Market Share and Forecast till 2031
March 28, 2023 | marketwatch.com
Ipratropium Bromide Market Share and Forecast till 2028
March 28, 2023 | marketwatch.com
Asthma and COPD Drugs Market Outlook and Forecast till 2031
March 27, 2023 | marketwatch.com
Oral Drug Delivery Market Growth and Forecast till 2031
March 24, 2023 | marketwatch.com
Medical Suction Catheters Market Size, Share, Growth | Global Report, 2031
See More Headlines
Receive VEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vectura Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Current Symbol
LON:VEC
CUSIP
N/A
CIK
N/A
Web
www.vectura.com
Phone
+44-1249-667700
Fax
N/A
Employees
9,200
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
8.20
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.77
Current Ratio
3.59
Quick Ratio
3.20

Sales & Book Value

Annual Sales
£190.60 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
12.48
Book Value
GBX 91.70 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
613,892,000
Free Float
N/A
Market Cap
£1.01 billion
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. William Downie (Age 54)
    CEO & Exec. Director
    Comp: $538.92k
  • Mr. Paul Andrew Fry (Age 54)
    CFO & Exec. Director
    Comp: $807k
  • Mr. Anthony Fitzpatrick
    Exec. VP of Operations
  • Dr. Geraldine Venthoye
    Chief Scientific Officer & Exec. VP of Product Devel.
  • Elizabeth Knowles
    VP of Investor Relations
  • Mr. John Murphy (Age 68)
    Gen. Counsel & Company Sec.
  • David Ginivan
    VP of Corp. Communications
  • Ms. Christina Olsen
    Exec. VP of Corp. Strategy & Communications
  • Ms. Joanne Hombal (Age 47)
    Exec. VP of HR
  • Mr. Roger Heerman (Age 48)
    Exec. VP of Commercial & Bus. Devel.

Key Competitors

View All Competitors

VEC Stock Analysis - Frequently Asked Questions

Is Vectura Group a good dividend stock?

Vectura Group (LON:VEC) pays an annual dividend of GBX 38 per share and currently has a dividend yield of 23.06%. VEC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 189.05%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for VEC.

What other stocks do shareholders of Vectura Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vectura Group investors own include Hikma Pharmaceuticals (HIK), SEB (SKP), BTG (BTG), iRobot (IRBT), Sinclair Pharma (SPH), Sirius Minerals (SXX), Coats Group (COA), Griffin Mining (GFM), HSBC (HSBA) and Inmarsat (ISAT).

How do I buy shares of Vectura Group?

Shares of VEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:VEC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research